Acrivon Therapeutics, Inc.
ACRV
$2.06
-$0.04-1.91%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 14.48% | 3.24% | 16.85% | 18.75% | -11.75% |
| Total Depreciation and Amortization | 20.90% | 23.15% | 19.14% | 39.04% | 46.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -36.37% | -28.92% | 14.18% | 53.02% | 48.70% |
| Change in Net Operating Assets | 180.77% | -16.88% | -104.68% | -32.26% | -97.36% |
| Cash from Operations | 10.52% | -5.13% | 12.23% | 29.09% | -19.47% |
| Capital Expenditure | 82.35% | 75.86% | 73.52% | 9.10% | -259.85% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -24.62% | -31.81% | 42.68% | -59.94% | 122.69% |
| Cash from Investing | -23.16% | -31.68% | 49.35% | -63.08% | 122.09% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | 64.95% | 90.41% | 70.32% | 90.23% | 80.98% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 7,593.81% | 90.38% | 70.32% | 92.22% | -100.08% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 168.00% | -1,021.08% | 269.54% | -130.43% | -87.18% |